Knott David M Jr Increases Stock Position in Viridian Therapeutics, Inc. $VRDN

Knott David M Jr grew its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 27.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 116,574 shares of the company’s stock after buying an additional 25,091 shares during the period. Viridian Therapeutics makes up 1.0% of Knott David M Jr’s investment portfolio, making the stock its 18th largest position. Knott David M Jr’s holdings in Viridian Therapeutics were worth $2,516,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of VRDN. US Bancorp DE increased its stake in shares of Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after acquiring an additional 463 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Viridian Therapeutics by 1.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after acquiring an additional 876 shares during the period. Knights of Columbus Asset Advisors LLC boosted its stake in Viridian Therapeutics by 2.4% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 59,410 shares of the company’s stock worth $1,282,000 after acquiring an additional 1,386 shares in the last quarter. Swiss National Bank boosted its stake in Viridian Therapeutics by 1.3% during the second quarter. Swiss National Bank now owns 108,900 shares of the company’s stock worth $1,522,000 after acquiring an additional 1,400 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of Viridian Therapeutics by 332.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock worth $42,000 after purchasing an additional 1,491 shares in the last quarter.

Viridian Therapeutics Stock Performance

Shares of VRDN stock opened at $28.34 on Friday. The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08. The company has a 50 day moving average price of $30.73 and a 200-day moving average price of $26.79. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $34.29. The firm has a market capitalization of $2.90 billion, a PE ratio of -8.61 and a beta of 1.00.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.18). The company had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $15.75 million. Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%. As a group, equities research analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Insiders Place Their Bets

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 2,272 shares of the stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total value of $70,795.52. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.58% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on VRDN shares. UBS Group assumed coverage on Viridian Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 target price on the stock. Wedbush upped their price objective on Viridian Therapeutics from $42.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Wall Street Zen downgraded Viridian Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Evercore reissued an “outperform” rating and issued a $44.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 20th. Finally, William Blair began coverage on Viridian Therapeutics in a research note on Wednesday, December 3rd. They issued an “outperform” rating for the company. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.43.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.